Ocugen Research Development vs Non Operating Income Net Other Analysis

OCGN Stock

USD 1.73 0.14 8.81%

Ocugen financial indicator trend analysis is much more than just breaking down Ocugen Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ocugen Inc is a good investment. Please check the relationship between Ocugen Research Development and its Non Operating Income Net Other accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Research Development vs Non Operating Income Net Other

Research Development vs Non Operating Income Net Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ocugen Inc Research Development account and Non Operating Income Net Other. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Ocugen's Research Development and Non Operating Income Net Other is 0.11. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Non Operating Income Net Other in the same time period over historical financial statements of Ocugen Inc, assuming nothing else is changed. The correlation between historical values of Ocugen's Research Development and Non Operating Income Net Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Ocugen Inc are associated (or correlated) with its Non Operating Income Net Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Operating Income Net Other has no effect on the direction of Research Development i.e., Ocugen's Research Development and Non Operating Income Net Other go up and down completely randomly.

Correlation Coefficient

0.11

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Research Development

Non Operating Income Net Other

Most indicators from Ocugen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ocugen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

At this time, Ocugen's Selling General Administrative is very stable compared to the past year. As of the 2nd of June 2024, Tax Provision is likely to grow to 0.00, while Issuance Of Capital Stock is likely to drop about 19.8 M.

Ocugen fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Other Assets	Long Term Debt
Total Assets		-0.41	0.67	0.88	0.32	-0.96	-0.35	0.75	0.98	0.35	0.65	0.99	0.65	0.71	-0.46	-0.23	0.62	-0.31	0.34	0.99	-0.33	0.65	0.63	0.49	0.31	0.55
Other Current Liab	-0.41		-0.01	-0.6	0.33	0.45	0.06	-0.44	-0.45	0.41	0.04	-0.48	-0.19	-0.06	0.59	-0.25	-0.38	0.57	0.32	-0.49	0.61	-0.16	0.12	-0.2	0.13	0.09
Total Current Liabilities	0.67	-0.01		0.52	0.85	-0.5	-0.69	0.73	0.54	0.87	0.93	0.58	0.74	0.84	-0.28	-0.19	0.63	-0.11	0.86	0.59	-0.35	0.78	0.95	0.66	-0.26	0.66
Total Stockholder Equity	0.88	-0.6	0.52		0.24	-0.87	-0.32	0.57	0.89	0.22	0.51	0.89	0.64	0.62	-0.82	-0.01	0.66	-0.72	0.26	0.89	-0.56	0.63	0.48	0.41	0.17	0.39
Property Plant And Equipment Net	0.32	0.33	0.85	0.24		-0.18	-0.75	0.34	0.22	0.98	0.78	0.22	0.59	0.7	-0.18	-0.26	0.52	-0.07	1.0	0.22	-0.29	0.64	0.82	0.45	-0.37	0.47
Net Debt	-0.96	0.45	-0.5	-0.87	-0.18		0.25	-0.64	-1.0	-0.19	-0.49	-0.99	-0.55	-0.59	0.45	0.28	-0.53	0.35	-0.19	-0.98	0.28	-0.53	-0.47	-0.33	-0.44	-0.37
Retained Earnings	-0.35	0.06	-0.69	-0.32	-0.75	0.25		-0.39	-0.28	-0.68	-0.65	-0.3	-0.51	-0.57	0.27	0.44	-0.86	0.16	-0.76	-0.28	0.57	-0.54	-0.56	-0.67	0.49	-0.27
Accounts Payable	0.75	-0.44	0.73	0.57	0.34	-0.64	-0.39		0.66	0.37	0.57	0.72	0.37	0.46	-0.22	-0.13	0.49	-0.06	0.34	0.72	-0.17	0.39	0.56	0.58	-0.13	0.43
Cash	0.98	-0.45	0.54	0.89	0.22	-1.0	-0.28	0.66		0.24	0.53	0.99	0.59	0.63	-0.47	-0.27	0.56	-0.36	0.24	0.99	-0.31	0.58	0.52	0.37	0.41	0.42
Non Current Assets Total	0.35	0.41	0.87	0.22	0.98	-0.19	-0.68	0.37	0.24		0.82	0.25	0.6	0.72	-0.1	-0.29	0.45	0.02	0.98	0.24	-0.15	0.64	0.87	0.48	-0.28	0.56
Non Currrent Assets Other	0.65	0.04	0.93	0.51	0.78	-0.49	-0.65	0.57	0.53	0.82		0.56	0.88	0.94	-0.28	-0.13	0.61	-0.13	0.8	0.58	-0.39	0.9	0.96	0.74	-0.09	0.76
Cash And Short Term Investments	0.99	-0.48	0.58	0.89	0.22	-0.99	-0.3	0.72	0.99	0.25	0.56		0.6	0.64	-0.46	-0.26	0.58	-0.34	0.24	1.0	-0.32	0.59	0.54	0.42	0.35	0.44
Common Stock Total Equity	0.65	-0.19	0.74	0.64	0.59	-0.55	-0.51	0.37	0.59	0.6	0.88	0.6		0.97	-0.47	-0.02	0.58	-0.37	0.61	0.62	-0.61	1.0	0.85	0.59	0.0	0.72
Common Stock Shares Outstanding	0.71	-0.06	0.84	0.62	0.7	-0.59	-0.57	0.46	0.63	0.72	0.94	0.64	0.97		-0.38	-0.12	0.61	-0.25	0.72	0.66	-0.51	0.98	0.93	0.61	0.02	0.75
Non Current Liabilities Total	-0.46	0.59	-0.28	-0.82	-0.18	0.45	0.27	-0.22	-0.47	-0.1	-0.28	-0.46	-0.47	-0.38		-0.26	-0.54	0.98	-0.19	-0.47	0.69	-0.46	-0.23	-0.25	0.17	-0.14
Other Current Assets	-0.23	-0.25	-0.19	-0.01	-0.26	0.28	0.44	-0.13	-0.27	-0.29	-0.13	-0.26	-0.02	-0.12	-0.26		-0.34	-0.31	-0.25	-0.2	-0.22	-0.03	-0.14	-0.22	-0.05	-0.1
Other Stockholder Equity	0.62	-0.38	0.63	0.66	0.52	-0.53	-0.86	0.49	0.56	0.45	0.61	0.58	0.58	0.61	-0.54	-0.34		-0.41	0.53	0.57	-0.7	0.6	0.5	0.73	-0.3	0.35
Total Liab	-0.31	0.57	-0.11	-0.72	-0.07	0.35	0.16	-0.06	-0.36	0.02	-0.13	-0.34	-0.37	-0.25	0.98	-0.31	-0.41		-0.07	-0.35	0.66	-0.35	-0.08	-0.1	0.14	0.02
Property Plant And Equipment Gross	0.34	0.32	0.86	0.26	1.0	-0.19	-0.76	0.34	0.24	0.98	0.8	0.24	0.61	0.72	-0.19	-0.25	0.53	-0.07		0.23	-0.3	0.66	0.83	0.46	-0.36	0.49
Total Current Assets	0.99	-0.49	0.59	0.89	0.22	-0.98	-0.28	0.72	0.99	0.24	0.58	1.0	0.62	0.66	-0.47	-0.2	0.57	-0.35	0.23		-0.34	0.61	0.56	0.43	0.36	0.46
Intangible Assets	-0.33	0.61	-0.35	-0.56	-0.29	0.28	0.57	-0.17	-0.31	-0.15	-0.39	-0.32	-0.61	-0.51	0.69	-0.22	-0.7	0.66	-0.3	-0.34		-0.6	-0.29	-0.39	0.38	-0.07
Common Stock	0.65	-0.16	0.78	0.63	0.64	-0.53	-0.54	0.39	0.58	0.64	0.9	0.59	1.0	0.98	-0.46	-0.03	0.6	-0.35	0.66	0.61	-0.6		0.88	0.62	-0.04	0.73
Short Long Term Debt Total	0.63	0.12	0.95	0.48	0.82	-0.47	-0.56	0.56	0.52	0.87	0.96	0.54	0.85	0.93	-0.23	-0.14	0.5	-0.08	0.83	0.56	-0.29	0.88		0.61	-0.1	0.78
Current Deferred Revenue	0.49	-0.2	0.66	0.41	0.45	-0.33	-0.67	0.58	0.37	0.48	0.74	0.42	0.59	0.61	-0.25	-0.22	0.73	-0.1	0.46	0.43	-0.39	0.62	0.61		-0.29	0.63
Other Assets	0.31	0.13	-0.26	0.17	-0.37	-0.44	0.49	-0.13	0.41	-0.28	-0.09	0.35	0.0	0.02	0.17	-0.05	-0.3	0.14	-0.36	0.36	0.38	-0.04	-0.1	-0.29		0.13
Long Term Debt	0.55	0.09	0.66	0.39	0.47	-0.37	-0.27	0.43	0.42	0.56	0.76	0.44	0.72	0.75	-0.14	-0.1	0.35	0.02	0.49	0.46	-0.07	0.73	0.78	0.63	0.13

Click cells to compare fundamentals

Ocugen Account Relationship Matchups

Ocugen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	16.8M	27.4M	105.8M	108.6M	64.5M	48.2M
Other Current Liab	206.0K	9.8K	293K	(1.3M)	2.8M	3.0M
Total Current Liabilities	4.5M	3.6M	7M	18.5M	17.1M	17.9M
Total Stockholder Equity	11.0M	21.6M	95.8M	84.1M	40.6M	22.2M
Property Plant And Equipment Net	222.5K	633.0K	1.2M	6.1M	17.3M	18.2M
Net Debt	(6.0M)	(21.5M)	(91.7M)	(71.2M)	(32.5M)	(34.1M)
Retained Earnings	(51.5M)	(73.3M)	(131.7M)	(213.0M)	(286.2M)	(271.9M)
Accounts Payable	1.9M	395.0K	2.3M	8.1M	3.2M	2.8M
Cash	7.4M	24.0M	95.0M	77.6M	39.5M	37.6M
Non Current Assets Total	1.0M	1.5M	3.1M	10.1M	21.6M	22.7M
Non Currrent Assets Other	667.7K	714.5K	1.8M	3.1M	3.4M	3.5M
Cash And Short Term Investments	7.4M	24.0M	95.0M	90.9M	39.5M	38.9M
Common Stock Total Equity	513K	527.5K	1.8M	2.0M	2.3M	2.4M
Common Stock Shares Outstanding	13.9M	112.2M	195.0M	214.6M	244.3M	256.5M
Liabilities And Stockholders Equity	16.8M	27.4M	105.8M	108.6M	64.5M	48.2M
Non Current Liabilities Total	1.2M	2.2M	2.9M	6.1M	6.9M	13.1M
Other Current Assets	8.3B	1.8B	7.7M	7.6M	3.5M	3.3M
Other Stockholder Equity	62.0M	93.0M	225.5M	294.8M	324.1M	190.6M
Total Liab	5.8M	5.8M	9.9M	24.6M	24.0M	18.9M
Property Plant And Equipment Gross	222.5K	633.0K	1.5M	6.7M	18.5M	19.4M
Total Current Assets	15.8M	25.9M	102.6M	98.5M	43.0M	42.0M
Accumulated Other Comprehensive Income	(10.9M)	(10.3M)	0.0	26K	20K	21K
Common Stock	527.5K	1.8M	2.0M	2.2M	2.6M	2.7M
Short Long Term Debt Total	1.4M	2.5M	3.3M	6.4M	6.9M	7.3M
Current Deferred Revenue	2.3M	2.9M	4.0M	11.2M	10.5M	5.6M
Other Assets	474.2K	432.1K	2.0M	177K	203.6K	193.4K
Long Term Debt	1.1M	1.8M	1.7M	2.3M	2.8M	1.5M
Capital Surpluse	215.9M	62.0M	93.1M	225.5M	203.0M	137.0M
Short Term Debt	172.3K	278.4K	363K	498K	574K	1.0M
Property Plant Equipment	222.5K	1.1M	1.2M	10.0M	11.5M	12.0M
Net Tangible Assets	11.0M	21.6M	95.8M	84.1M	96.7M	101.5M
Net Invested Capital	12.1M	23.6M	97.5M	86.3M	43.4M	39.5M
Net Working Capital	11.2M	22.3M	95.6M	80.0M	25.9M	39.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Ocugen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ocugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ocugen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ocugen Inc Stock:

How To Invest In Ocugen

Details

Is Ocugen Stock a good investment?

Details

What is Ocugen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Note that the Ocugen Inc information on this page should be used as a complementary analysis to other Ocugen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Ocugen Stock analysis

When running Ocugen's price analysis, check to measure Ocugen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocugen is operating at the current time. Most of Ocugen's value examination focuses on studying past and present price action to predict the probability of Ocugen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ocugen's price. Additionally, you may evaluate how the addition of Ocugen to your portfolios can decrease your overall portfolio volatility.

	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Transaction History View history of all your transactions and understand their impact on performance
	CEOs Directory Screen CEOs from public companies around the world
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated

Is Ocugen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.23)

Revenue Per Share

0.026

Quarterly Revenue Growth

1.289

Return On Assets

(0.50)

Return On Equity

(1.09)

The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ocugen Research Development vs Non Operating Income Net Other Analysis

Research Development vs Non Operating Income Net Other

Research Development vs Non Operating Income Net Other Correlation Analysis

Correlation Coefficient

Research Development

Non Operating Income Net Other

Ocugen fundamental ratios Correlations

Ocugen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ocugen fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Ocugen Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.96	Total Assets
Net Debt	- 0.87	Total Stockholder Equity
Other Stockholder Equity	- 0.86	Retained Earnings